Bendamustine plus rituximab versus CHOP plus rituximabas first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - Rummel, MJ; Niederle, N; Maschmeyer, G (Lancet, 2013)